Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.

Rong-Rong Li,Xian-Li Yin,De-Yu Zeng, Feng-Jiang Shao,Seiichiro Yamamoto,Wu Liu,Zhen-Yang Liu

Annals of translational medicine（2022）

引用 2|浏览23

暂无评分

摘要

The combination of regorafenib plus anti-PD-1 antibodies has a manageable safety profile and may improve prognosis for pMMR/MSS mCRC patients, especially those who received >1 cycle. Compared to the other anti-PD-1 antibodies, sintilimab may be more efficacious; however, further prospective studies need to be conducted to confirm our findings.

查看译文

关键词

Colorectal cancer,immune checkpoint inhibitor,microsatellite stable (MSS),programmed cell death protein 1 (PD-1),regorafenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要